HORIZON (OP-106) study of melflufen in patients with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab and/or pomalidomide: updated efficacy and safety

Autores: Richardson, P. G. ; Oriol, A.; Larocca, A. ; Rodríguez Otero, Paula; Norkin, M.; Blade, J. ; Cavo, M.; Hassoun, H. ; Leleu, X. ; Alegre, A.; Maisel, C.; Paner, A.; Mazumder, A.; Zonder, J. A.; Puig, N.; Harran, J. ; Harmenberg, J.; Thuresson, S.; Zubair, H.; Mateos, M. V.